On this page
Pharma PLI draws ₹46,744 crore, but China’s API import share rises to 73.7%
Our read
India will add domestic API capacity without quickly reducing China dependence; the near-term retail risk is not broad medicine scarcity but episodic generic-drug cost inflation and SKU-level availability disruption during any China-linked supply shock.
For operators
Strengthen API sourcing resilience through supplier diversification, strategic inventory and domestic-vendor qualification as China’s import share has climbed to 73.7% despite PLI-led capacity additions.
Watch
China API/KSM export controls, anti-dumping actions, environmental inspections or freight-rate spikes.
The report,
India’s pharma PLI schemes drew Rs 46,744 crore of investment, exceeding targets and expanding domestic API and device capacity. However, Chinese dependence remains high, with China’s share of India’s API, KSM and intermediate imports rising to 73.7% in FY25.
Reported figures
From the report. Source details below
| Rs 46,744 crore PLI investment as of June | 2026 |
|---|---|
| 39 commissioned projects covering | 28 APIs |
| 11.5% investment growth from December 2025 to June | 2026 |
| China API/KSM/intermediate imports: | Rs 18,646 crore in FY21 and Rs 27,032 crore in FY25 |
| China import share: | 68.2% in FY21 and 73.7% in FY25 |
Also in the report
- Rs 17,275 crore investment target
- Rs 4.03 lakh crore total sales
- Rs 2.57 lakh crore exports
- Rs 5,210.74 crore bulk-drug PLI investment
- Rs 4,330 crore committed bulk-drug investment
- 20.2% cumulative sales growth
- 191 of 726 APIs, KSMs and intermediates produced in India for the first time
- 57 high-end medical devices produced domestically
- 3 bulk-drug parks approved
Other figures
- 1.21 lakh jobs
Why it matters to operators
Prioritize partnerships, acquisitions or long-term offtake deals in Indian API, KSM and intermediate manufacturing to convert policy-supported capacity growth into lower import exposure.
What to watch next
- Monthly import data showing sustained further growth in China share or sharp increases in API/KSM unit prices.
- NPPA price revisions, shortage notifications or changes to the National List of Essential Medicines.
- PLI scheme revisions linking incentives to domestic value addition, minimum capacity utilization or government procurement.
- Commercial commissioning and USFDA/CDSCO approvals for Indian API and bulk-drug-park facilities.
- Inventory days and gross-margin commentary from Indian drug formulators, distributors and organized pharmacy chains.
Likely next moves
Our read of what comes next — analysis, not reported by the source.
- Audit exposure to high-volume essential medicines whose APIs, KSMs or intermediates are predominantly China sourced.
- Increase safety-stock and dual-sourcing requirements for antibiotics, pain management, diabetes, cardiovascular and chronic-care products with constrained supplier bases.
- Track whether branded-generic manufacturers pass API inflation through to distributors, hospitals and pharmacy retailers or absorb it through margin compression.
- Favor supplier contracts with price-adjustment clauses, supply guarantees and origin-level traceability rather than relying on country-of-invoice data.
- For pharmacy retailers, expand substitution protocols and customer communication for equivalent generics if specific SKUs face availability gaps.
Show 1 more
- Monitor PLI beneficiaries for actual commercial output, utilization rates, regulatory approvals and customer offtake rather than announced capex alone.
The counter-case
The case against this reading — not reported by the source.
The headline risks overstating PLI failure by treating higher China-sourced import value as proof that domestic capacity has not improved. Import dependence can rise in rupee terms because overall pharma output, exports, and demand for intermediates expanded faster than newly commissioned domestic plants; it can also reflect Chinese price competitiveness, product-mix shifts toward complex APIs, and the long lead time between PLI investment approvals and commercial-scale output. ₹46,744 crore of committed or reported investment is not equivalent to operating capacity, but neither is ₹27,032 crore of imports evidence that all PLI-supported capacity is ineffective. The more relevant test is dependence in strategically critical molecules, domestic capacity utilization, quality consistency, and whether India can switch suppliers during a disruption—not aggregate import share alone.
The source
Published
First seen